Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
about
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age GroupsGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Hemoglobin, Anemia, and Cognitive Function: The Atherosclerosis Risk in Communities Study.Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey.Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013.Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.A portable microfluidic platform for rapid molecular diagnostic testing of patients with myeloproliferative neoplasmsRecent advances in the diagnosis and management of primary myelofibrosis.The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting.Cytoreductive treatment patterns among US veterans with polycythemia vera.
P2860
Q26786893-804162D3-36B7-4315-BCDC-7FBF57871FCDQ30276550-31407A6C-F945-40A7-B47F-C024089FD7F8Q31169518-4BF25633-9F9B-4849-940B-BF4D09C99338Q36782943-9F2B0D77-A814-48C1-9097-484868D0D4BCQ36954901-42E15494-7F78-403A-A0D2-7F617949BAE5Q37599270-0B2B7D82-54A4-443B-B1E4-07AE0DE57DE2Q38938526-F92F983F-BA92-42E9-A1CF-C177256B2A82Q39061404-BD9F468F-65B5-4A32-A140-4A393B86C071Q39513246-A2596C2E-6E09-42CB-A4E5-EA3CB55BECA9Q40497461-4CF6B326-24BF-458D-ABAE-CAF272E63183Q41447065-42046640-B470-4394-AA75-D8B6EF61BE5BQ54980872-2B91FBBC-0EB9-46CE-858C-A15741236826Q55284640-AFF3B58C-5769-4A41-B418-38D68F01898FQ55286543-1338332B-3990-4FE0-8861-4BD4B2921948
P2860
Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Changing incidence of myelopro ...... rofiles in the USA, 1973-2011.
@en
type
label
Changing incidence of myelopro ...... rofiles in the USA, 1973-2011.
@en
prefLabel
Changing incidence of myelopro ...... rofiles in the USA, 1973-2011.
@en
P2860
P1476
Changing incidence of myelopro ...... rofiles in the USA, 1973-2011.
@en
P2093
Melissa A Deadmond
P2860
P2888
P304
P356
10.1007/S00432-015-1983-5
P577
2015-05-13T00:00:00Z